Below are Rx IP Update’s most-read articles of 2021 (see also our 2021 Highlights in Canadian Life Sciences IP and Regulatory Law):
- Federal Court remits BELSOMRA CSP timing refusal for redetermination
- Update on biosimilars in Canada – October 2021
- Health Canada paving the way for more AI/ML medical devices
- First year of Project Orbis leads to 38 approvals of cancer therapies, including 8 by Health Canada
- Patentability of diagnostic methods – has the Canadian Patent Office drawn the line?
- New CADTH Report on Health Technology Trends in 2021
- FCA upholds reconsideration decision maintaining $100M+ award against Apotex for cefaclor patent infringement
- Federal Court decision regarding glatiramer acetate finds one patent obvious and another valid and infringed
- Supreme Court of Canada denies Amgen leave to appeal decision invalidating its filgrastim patent
- Federal Court of Appeal upholds decision finding Seedlings' LifeCard patent invalid and not infringed by Pfizer’s EpiPen
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group or the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Twice is not nice – second notice of allegation may be abusive
On December 23, 2023, the Federal Court of Appeal (FCA) held that it was an abuse of process for Apotex to raise invalidity in defending actions under the Patented Medicines (Notice of Compliance) Reg...Read More -
FCA upholds inducement of infringement findings relating to paliperidone palmitate
On January 12, 2024, the Federal Court of Appeal (FCA) dismissed both appeals: Apotex Inc v Janssen Inc, 2024 FCA 9 and Pharmascience Inc v Janssen Inc, 2024 FCA 10.Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More